^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    BCMA-targeted CAR-T immunotherapy

    Related drugs:
    5d
    CARTINUE: A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel (clinicaltrials.gov)
    P4, N=295, Recruiting, Janssen Research & Development, LLC | Trial completion date: Jan 2038 --> Jun 2042
    Trial completion date
    |
    Carvykti (ciltacabtagene autoleucel)
    6d
    Universal CAR-T Cells (REVO-UWD-00B) for Refractory and Relapsed Multiple Myeloma (clinicaltrials.gov)
    P1, N=30, Suspended, Wondercel Biotech (ShenZhen) | Recruiting --> Suspended
    Trial suspension
    |
    fludarabine IV
    7d
    D8311C00001: A trial to learn how well AZD0120 works and how safe it is in people with relapsed or refractory multiple myeloma. (2025-523285-25-00)
    P2/3, N=153, Not yet recruiting, AstraZeneca AB
    New P2/3 trial
    |
    bortezomib • Darzalex (daratumumab) • carfilzomib • pomalidomide • AZD0120
    8d
    Detection of cytokine release syndrome using wearables and cytokine profiling following CAR-T therapy for myeloma. (PubMed, JCI Insight)
    Wearable devices are feasible for early CRS detection and may support outpatient CAR-T care. Larger outpatient studies are warranted.
    Journal • IO biomarker
    |
    IFNG (Interferon, gamma)
    |
    Abecma (idecabtagene vicleucel) • Carvykti (ciltacabtagene autoleucel)
    10d
    D8311C00001: A trial to learn how well AZD0120 works and how safe it is in people with relapsed or refractory multiple myeloma. (2025-523285-25-00)
    P2/3, N=38, Not yet recruiting, AstraZeneca AB
    New P2/3 trial
    |
    bortezomib • Darzalex (daratumumab) • carfilzomib • pomalidomide • AZD0120
    15d
    Clinical Study of Safety and Efficacy of Universal PSMA CAR- T in Refractory CRPC (clinicaltrials.gov)
    P1, N=3, Active, not recruiting, Shanghai Changzheng Hospital | Recruiting --> Active, not recruiting | Trial completion date: Nov 2025 --> Nov 2026 | Trial primary completion date: Nov 2025 --> Jul 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    FOLH1 (Folate hydrolase 1)
    |
    FOLH1 expression
    19d
    inMMyCAR: A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=70, Recruiting, Kelonia Therapeutics, Inc. | N=40 --> 70
    Enrollment change
    19d
    P-BCMA-ALLO1-001: P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma (clinicaltrials.gov)
    P1, N=275, Active, not recruiting, Poseida Therapeutics, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    RG6538 • rimiducid (AP1903)
    20d
    Descartes-08 in Autoantibody Myositis (clinicaltrials.gov)
    P2, N=60, Recruiting, Cartesian Therapeutics | Not yet recruiting --> Recruiting | Trial completion date: May 2027 --> May 2028 | Trial primary completion date: Nov 2026 --> Nov 2027
    Enrollment open • Trial completion date • Trial primary completion date
    |
    Descartes-08
    21d
    BCMA-CD19 cCAR T for the Treatment of Refractory Inflammatory Bowel Disease (IBD) (clinicaltrials.gov)
    P1/2, N=18, Not yet recruiting, iCell Gene Therapeutics
    New P1/2 trial
    22d
    Minimal Change Disease Following B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy. (PubMed, Kidney Med)
    We report a case of minimal change disease presenting with AKI and nephrotic-range proteinuria 3 weeks after B-cell maturation antigen-directed CAR-T cell therapy, ciltacabtagene autoleucel, in a patient with relapsed refractory multiple myeloma. The patient received one dose of rituximab along with a short course of corticosteroid and had complete kidney recovery by week 4 of therapy. This report emphasizes the need for further investigation into the mechanism of kidney toxicity following CAR-T cell therapy, and potential benefits and risks of immunosuppressive therapy in this context.
    Journal
    |
    CD4 (CD4 Molecule)
    |
    Rituxan (rituximab) • Carvykti (ciltacabtagene autoleucel)
    27d
    CAR-T Therapy Targeting CD19 and BCMA in Highly Sensitized Kidney Transplant Participants (clinicaltrials.gov)
    P1, N=12, Recruiting, Tongji Hospital | Not yet recruiting --> Recruiting
    Enrollment open • IO biomarker
    |
    IFNG (Interferon, gamma) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • SDC1 (Syndecan 1) • IL13 (Interleukin 13) • IL4 (Interleukin 4)
    |
    AZD0120